AstraZeneca's Lynparza OK'd in Japan for type of breast cancer [Seeking Alpha]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Seeking Alpha
AstraZeneca's Lynparza OK'd in Japan for type of breast cancerAstraZeneca (NYSE:AZN) and collaboration partner Merck (NYSE:MRK)announce that LYNPARZA (olaparib) has been approved in Japan for the treatment of patients with unresectable or recurrent BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received prior chemotherapy.The data supporting the approval was generated in the Phase 3 OlympiAD study that showed Lynparza extended progression-free survival (PFS) versus chemo (median of 7.0 months vs. 4.2 months).LYNPARZA was first approved in Japan for maintenance treatment of platinum-resistant relapsed ovarian cancer.AZN is down1% premarket on light volume.See all stocks on the move »Now read:Roche Won't Go Down Without A Fight In The Front-Line Cancer Arena »
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Borderline Personality Disorder (BPD) Global Clinical Trials Review 2024: Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End-Point Status [Yahoo! Finance]Yahoo! Finance
- Life prolonging breast cancer drug recommended for PBS subsidy, but it is not time to celebratePR Web
- Global Antibiotics Market Analysis Report 2024-2030: Penicillin Drug Class Segment Led the Market in 2023, the Cephalosporin Segment is Anticipated to Register the Fastest CAGR from 2024 to 2030 [Yahoo! Finance]Yahoo! Finance
- Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order [Yahoo! Finance]Yahoo! Finance
- AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain' [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 4/25/24 - Form 6-K
- 4/11/24 - Form 6-K
- 4/11/24 - Form 6-K
- AZN's page on the SEC website